Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $28.44 and last traded at $27.6790, with a volume of 137106 shares traded. The stock had previously closed at $25.59.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. JonesTrading reduced their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Wedbush cut their price target on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Thursday, April 2nd. Jefferies Financial Group restated a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a report on Monday, March 16th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday. Finally, Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Price Performance

The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The firm’s fifty day moving average price is $21.76 and its two-hundred day moving average price is $16.80. The stock has a market capitalization of $789.23 million, a PE ratio of -11.34 and a beta of 2.01.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. On average, equities analysts predict that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC boosted its position in Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the last quarter. Peapod Lane Capital LLC lifted its stake in shares of Alto Neuroscience by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after purchasing an additional 3,106 shares during the period. Torren Management LLC purchased a new position in shares of Alto Neuroscience in the fourth quarter worth approximately $62,000. XTX Topco Ltd boosted its holdings in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the last quarter. Finally, Citizens Financial Group Inc. RI grew its position in Alto Neuroscience by 19.0% during the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after buying an additional 6,394 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.